Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Neurocrine Biosciences (NBIX) and maintained a $155 price target.
April 10, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Neurocrine Biosciences with a $155 price target.
The reaffirmation of an Overweight rating and a high price target by a reputable analyst like Charles Duncan suggests a strong vote of confidence in Neurocrine Biosciences. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in NBIX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100